Penn researchers say they now can detect Alzheimer’s at earliest stage - Technical.ly Philly

Mar. 18, 2009 8:30 am

Penn researchers say they now can detect Alzheimer’s at earliest stage

Fighting Alzheimer’s may get easier because of research from the University of Pennsylvania’s School of Medicine. Researchers there have announced that they have validated a test capable of confirming the incurable, degenerative disease at its earliest stages, increasing the opportunity to find methods to slow or eventually stop the effects, according to a university press […]

Fighting Alzheimer’s may get easier because of research from the University of Pennsylvania’s School of Medicine.

Researchers there have announced that they have validated a test capable of confirming the incurable, degenerative disease at its earliest stages, increasing the opportunity to find methods to slow or eventually stop the effects, according to a university press release.

The test measures cerebrospinal fluid concentrations of  amyloid beta42 peptide and tau protein, two of the disease’s trademarks.

“With this test, we can reliably detect and track the progression of Alzheimer’s disease,” said Dr. Leslie M. Shaw, who led the research. “Validated biomarker tests will improve the focus of Alzheimer’s clinical trials, enrolling patients at earlier stages of the disease to find treatments that can at least delay –and perhaps stop– neurodegeneration. In addition, prevention trials can test methods to delay or block mild cognitive impairment from converting to full-blown Alzheimer’s.”

The test can confirm whether a patient will suffer from the disease before dementia and most irreversible damage occurs. The researchers say the findings may help in the search of effective therapies capable of stopping the disease, which affects some four million Americans.

Further validation studies are underway at the Ivy League school in University City.

In related news yesterday, another Penn research team announced that they had identified a new protein important in the breast cancer gene’s role in DNA repair.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Jefferson’s Bon Ku brings health design principles to his primetime TV debut

Penn Nursing is hosting a yearlong innovation accelerator

Exton cell and gene therapy company Fibrocell will be acquired for $63.3M

SPONSORED

Philly

These hiring companies want to meet you at NET/WORK Suburbs

Philadelphia

Perpay

UX Designer

Apply Now

Chesterbrook, PA

Deacom

Inside Sales Representative

Apply Now

Horsham, PA

Penn Mutual

Product Owner/Business Transformation Specialist

Apply Now

Indy Hall has a plan to provide healthcare to freelancers

What this Penn nursing student found in his Fulbright research on gaming

The City is hosting a ‘Hire Hahnemann’ job fair for soon-to-be-displaced employees

SPONSORED

Philly

Mastering the ‘halo effect’ in tech recruiting

Center City

Inspire

Member Experience Specialist

Apply Now

Philadelphia, PA

Perpay

Frontend Engineer

Apply Now

Philadelphia

Perpay

Senior Data Scientist

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!